RxDoctor Payments DataLook up a doctor →

Edward Filippone, MD

Nephrology · Phila, PANPI 1649211129

Payments from drug & device makers

$146,115in general payments, 2019–2025

Across 656 payments — averaging $222.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$79K
  • Boehringer Ingelheim$43K
  • Otsuka America Pharmaceutical, Inc.$7K
  • Otsuka Pharmaceutical Development & Commercialization, Inc.$5K
  • AstraZeneca$2K
  • Vifor Pharma, Inc.$2K
  • plus $7K from 16 others

What the payments were for

  • Consulting fees$11,0048%
  • Speaking & faculty fees$117,49580%
  • Travel & lodging$5,7924%
  • Food & beverage$11,5058%
  • Education$3190%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$146,115 in reported general payments places this provider in the 95th percentile of 586 nephrology providers in Pennsylvania.

See all nephrology providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$104,816
Medicare patients
241
Services billed
974

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin497$376,751
KerendiaFinerenone148$115,763
FarxigaDapagliflozin Propanediol125$93,025
RayaldeeCalcifediol43$51,869
VemlidyTenofovir Alafenamide22$30,184
EliquisApixaban18$10,457
OzempicSemaglutide11$10,092
DapagliflozinDapagliflozin Propanediol14$7,177
Ondansetron OdtOndansetron13$7,025
Cinacalcet Hcl26$6,267
Calcium Acetate56$4,176
Sevelamer Carbonate29$3,654
Chlorthalidone262$3,028
Losartan Potassium307$2,938
Amlodipine Besylate432$2,180

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$43,175$376,751497 claims
BayerKerendia$1,120$115,763148 claims
AstraZenecaFarxiga$2,362$93,025125 claims
OPKO Pharmaceuticals, LLCRayaldee$1,157$51,86943 claims
Novo NordiskOzempic$209$10,09211 claims
ANI Pharmaceuticals, Inc.Valsartan$255$40612 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 586 nephrology providers in Pennsylvania.

Other nephrology in Phila

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →